CAMBRIDGE, Mass., May 12, 2026
Mirai Bio unveiled new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting demonstrating rapid advancement of its CD8-targeted lipid nanoparticle (LNP) platform for in vivo CAR-T cell engineering. The company reported that it successfully advanced its targeted LNP system from initial particle design to functional non-human primate (NHP) proof-of-concept in only 10 months, highlighting the growing potential of next-generation RNA delivery technologies to transform cell therapy development. The findings reinforce increasing industry momentum toward in vivo CAR-T therapies, which aim to eliminate the complex manufacturing and hospitalization requirements associated with traditional ex vivo CAR-T treatments.
Mirai Demonstrates Functional In Vivo CAR-T Activity in Primates
Mirai Bio’s ASGCT 2026 presentations focused on the company’s proprietary CD8-targeted LNP delivery platform, designed to selectively deliver mRNA payloads directly into T cells while minimizing off-target liver exposure. According to the company, the targeted nanoparticles successfully generated CAR-expressing endogenous CD8+ T cells in non-human primates following systemic administration. The preclinical data also showed rapid and sustained depletion of circulating CD20+ B cells, an important proof-of-concept for the potential treatment of autoimmune diseases and hematologic cancers.
The company stated that a single dose of the CD8-targeted LNPs produced measurable CAR-T activity in primates while maintaining a tolerability profile supportive of further translational development. Researchers observed reduced off-target delivery, controlled cytokine responses, and no major clinical safety concerns throughout the study period. The ability to generate functional CAR-T cells directly inside the body represents a major technological shift compared with conventional autologous CAR-T manufacturing, which often requires weeks of cell collection, engineering, expansion, and reinfusion.
Mirai also presented data demonstrating that its optimized LNP formulations reduced hepatic expression while supporting extrahepatic delivery to immune cells. The company used a modular lipid discovery platform and machine learning-guided optimization to design novel ionizable lipids capable of improving tissue selectivity and T-cell targeting efficiency. These findings further strengthen the role of AI-guided LNP engineering in next-generation genetic medicine development.
Advertisement
Machine Learning Accelerates Next-Generation RNA Delivery
A key differentiator highlighted by Mirai Bio was the speed of development enabled by its integrated platform. The company emphasized that its machine learning-driven LNP optimization process enabled rapid translation from particle discovery to NHP validation in less than one year. This accelerated approach could significantly reduce development timelines for RNA therapeutics and in vivo immune cell engineering programs.
Mirai’s broader ASGCT presentations also included oral data describing machine learning-guided optimization of LNP delivery to adipose tissue, a growing research area for obesity and metabolic disease therapeutics. Together, the company’s ASGCT programs demonstrated how proprietary biodistribution datasets, AI-driven particle design, and scalable manufacturing capabilities are becoming increasingly important in nucleic acid medicine development.
Industry interest in targeted LNP platforms has rapidly increased as multiple biotechnology companies pursue in vivo CAR-T strategies capable of simplifying cancer immunotherapy delivery. Compared with traditional ex vivo CAR-T therapies, in vivo approaches could potentially improve accessibility, reduce manufacturing costs, and expand treatment availability to broader patient populations. The ASGCT 2026 meeting featured multiple presentations from companies exploring targeted RNA delivery systems, highlighting the growing competitive focus on next-generation immune cell engineering technologies.
Mirai Positions Itself in Expanding Genetic Medicine Market
Mirai Bio stated that its CD8-targeted LNP platform creates a “cargo-ready” foundation for partner programs focused on oncology, autoimmune diseases, and immune-mediated disorders. The company aims to position itself as a strategic delivery partner for developers of nucleic acid medicines requiring precise tissue and cell targeting beyond the liver. With increasing investment flowing into RNA therapeutics, targeted nanoparticles, and programmable immune-cell engineering, Mirai’s ASGCT 2026 data place the company among emerging innovators attempting to redefine the future of genetic medicine and scalable CAR-T therapy development.
Source: Mirai Bio press release
